Data from the ANDROMEDA Study Show Haematologic Response for DARZALEX®▼ (daratumumab) Subcutaneous Formulation Combination Regimen in Newly Diagnosed Light Chain (AL) Amyloidosis
- EMEA Innovative Medicine
- Data from the ANDROMEDA Study Show Haematologic Response for DARZALEX®▼ (daratumumab) Subcutaneous Formulation Combination Regimen in Newly Diagnosed Light Chain (AL) Amyloidosis
Data from the ANDROMEDA Study Show Haematologic Response for DARZALEX®▼ (daratumumab) Subcutaneous Formulation Combination Regimen in Newly Diagnosed Light Chain (AL) Amyloidosis
- X (Twitter)
Copy link